Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1997 Oct;45(1):37–44. doi: 10.1007/s002620050398

Modulation of tumoricidal function in alveolar macrophages from lung cancer patients by interleukin-6

Mi-Chung Ahn 1, Kalliopi P Siziopikou 1, Janet M D Plate 1,2, Larry Casey 3, Mike Silver 3, Jules E Harris 1,2, Donald P Braun 1,2,✉
PMCID: PMC11037664  PMID: 9353425

Abstract

Previous studies have demonstrated that alveolar macrophages from lung cancer patients are impaired in their ability to develop tumoricidal function when stimulated by activators such as interferon γ + lipopolysaccharide. However, these same macrophages have been shown to develop significant tumoricidal function when precultured with macrophage-depleted allogeneic peripheral blood lymphocytes from normal donors, an effect that was lost by the elimination of natural killer cells from the allogeneic lymphocyte population. In the present study, the effect of each activation condition on the expression of mRNA for interleukin-1α (IL-1α), IL-1β, tumor necrosis factor α (TNFα) and IL-6 was determined using reverse transcription/polymerase chain reaction. The results show that the non-permissive activation condition is associated with the expression of mRNA for IL-6 while the permissive activation condition is not. Antibodies against IL-6 were subsequently shown to permit the development of tumoricidal function in alveolar macrophages stimulated with interferon γ + lipopolysaccharide while IL-6 protein was shown to inhibit the stimulatory action of allogeneic lymphocytes on the development of tumoricidal function in the same alveolar macrophages. Neither the permissive (i.e. allogeneic lymphocyte stimulation) nor the non-permissive (i.e. interferon γ + lipopolysaccharide) activation condition had any effect on the capacity of alveolar macrophages from lung cancer patients to express mRNA for IL-1α, IL-1β or TNFα These results show that IL-6 can regulate the ability of alveolar macrophages from lung cancer patients to be stimulated by interferon γ + lipopolysaccharide to develop significant tumoricidal function. They also show that allogeneic lymphocytes have the capacity to downregulate IL-6 mRNA synthesis by alveolar macrophages thereby permitting the development and/or expression of macrophage tumoricidal function.

Key words: Alveolar macrophages, Tumoricidal activity, PBL, Interleukin-6, Lung cancer

Footnotes

This work was supported in part by PHS grant no. 58922

References

  • 1.Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol. 1984;2:283–318. doi: 10.1146/annurev.iy.02.040184.001435. [DOI] [PubMed] [Google Scholar]
  • 2.Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78. doi: 10.1016/S0065-2776(08)60532-5. [DOI] [PubMed] [Google Scholar]
  • 3.Bataille R, Jorudan M, Zhang XG, Klein B. IL-6 is a potent grown factor for plasma cells and is elevated in overt myeloma and plasma cell leukemia. J Clin Invest. 1989;84:2008–2011. doi: 10.1172/JCI114392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Braun DP, Siziopikou KP, Casey L, Harris JE. Augmentation of impaired tumoricidal function in alveolar macrophages from lung cancer patients by cocultivation with allogeneic lymphocytes. Proc Am Assoc Cancer Res. 1990;31:244–244. [Google Scholar]
  • 5.De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209–1220. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Frishman J, Long B, Knospe W, Gregory S, Plate J. Genes for interleukin 7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia. J Exp Med. 1993;177:955–964. doi: 10.1084/jem.177.4.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gangmi JD, Olsen GN, Fechtez C, Hightower JA, Bauguess CT, Krech L. Phagocytic activity of alveolar macrophages in patients with bronchogenic carcinoma. Cancer Immunol Immunother. 1985;20:158–166. doi: 10.1007/BF00205683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gibbons R, Martinez O, Matli M, Heinel F, Bernstein M, Warren R. Recombinant IL-4 inhibits IL-6 synthesis by adherent peripheral blood cells in vitro. Lymphokine Res. 1990;9:283–293. [PubMed] [Google Scholar]
  • 9.Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manologas SC. Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883–891. doi: 10.1172/JCI115668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Guerne PA, Zuraw BI, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestation of arthritis. J Clin Invest. 1989;83:585–592. doi: 10.1172/JCI113921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Helfgott DC, May LT, Stoeger Z, Tamm I, Segal PB. Bacterial lipopolysaccharide enhances expression and secretion of β2 interferon by human fibroblast. J Exp Med. 1987;166:1300–1309. doi: 10.1084/jem.166.5.1300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Helle M, Brankenhoff J, Aarden L. Interleukin-6: its role in the cytokine network. In: van Furth R, editor. Mononuclear phagocytes. London New Yor: Kluwer Academic; 1992. pp. 333–339. [Google Scholar]
  • 13.Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatshuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F, Kishimoto T. Human B cell differentiation factor defined by anti-peptide antibody and its possible role in auto-antibody production. Proc Natl Acad Sci USA. 1987;84:228–231. doi: 10.1073/pnas.84.1.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kan-Mitchell J, Hengst JCD, Kempf RA, Rothbart RK, Simons SM, Brooker AS, Kortes VL, Mitchell MS. Cytotoxic activity of human pulmonary alveolar macrophages. Cancer Res. 1985;45:453–458. [PubMed] [Google Scholar]
  • 15.Klein B, Lu ZU, Bataille R. Clinical application of IL-6 inhibitors. Res Immunol. 1992;143:774–776. doi: 10.1016/0923-2494(92)80022-D. [DOI] [PubMed] [Google Scholar]
  • 16.Kohase M, Henriksen-DeStefano D, May LT, Vilcek J, Sehgal PB. Induction of β2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell. 1986;46:659–666. doi: 10.1016/0092-8674(86)90780-4. [DOI] [PubMed] [Google Scholar]
  • 17.Kuda T, Yasumoto K, Yano T, Nukahashi H, Sugimashi K, Nomoto K. Role of antitumor activity of alveolar macrophages in lung cancer patients. Cancer Res. 1987;47:2199–2202. [PubMed] [Google Scholar]
  • 18.Miles SA, Rezai AR, Salazar-Gonzales JF, Meyden MV, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, Martinez-Maza O. AIDS Kaposi’s sarcoma-derived cells produce and respond to interleukin-6. Proc Natl Acad Sci USA. 1990;87:4068–4072. doi: 10.1073/pnas.87.11.4068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Nakafaku M, Satoh T, Kaziro Y. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce accumulation of an active ras-GTP complex in rat pheochromocytoma PC 12 cells. J Biol Chem. 1992;267:19 448–19 454. [PubMed] [Google Scholar]
  • 20.Nakajima T, Wall R. Interleukin-6 signals activating junB and tis11 gene transcription in a B cell hybridoma. Mol Cell Biol. 1991;11:1409–1418. doi: 10.1128/mcb.11.3.1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S. Phosphorylation at threonine 235 by a ras dependent MAP kinase cascade is essential for transcriptional activation of NF-IL6. Proc Natl Acad Sci USA. 1993;90:2207–2211. doi: 10.1073/pnas.90.6.2207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma, as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158:670–689. doi: 10.1084/jem.158.3.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Natsuka S, Akira S, Sugita T, Hashimoto S, Nishio Y, Isshiki H, Kishimoto T. Macrophage differentiation specific expression of NF-IL-6, a transcription factor for IL-6. Blood. 1992;79:460–466. [PubMed] [Google Scholar]
  • 24.Sanceau J, Beranger F, Gaudelt C, Wietzerbin J. IFN-γ is an essential cosignal for triggering IFN-β2 gene expression in human monocytic cell lines. Ann N Y Acad Sci. 1989;557:130–143. doi: 10.1111/j.1749-6632.1989.tb24006.x. [DOI] [PubMed] [Google Scholar]
  • 25.Sehgal PB, Walther Z, Tamm I. Rapid enhancement of β2- IFN/BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc Natl Acad Sci USA. 1987;84:3633–3667. doi: 10.1073/pnas.84.11.3663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory production by the antirheumatic Tenidap and Naproxen. A possible correlate with clinical acute phase response. J Immunol. 1992;148:480–484. [PubMed] [Google Scholar]
  • 27.Siziopikou KP, Harris JE, Casey L, Nawas Y, Braun DP. Impaired tumoricidal function of alveolar macrophages from patients with non-small cell lung cancer. Cancer. 1991;68:1035–1044. doi: 10.1002/1097-0142(19910901)68:5<1035::AID-CNCR2820680522>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  • 28.Sone SO. Role of alveolar macrophages in pulmonary neoplasias. Biochim Biophys Acta. 1986;823:2227–2245. doi: 10.1016/0304-419x(86)90004-1. [DOI] [PubMed] [Google Scholar]
  • 29.Swinburne S, Moore M, Cole P. Human bronchoalveolar macrophage cytotoxicity for cultured human lung tumor cells. Br J Cancer. 1982;46:625–634. doi: 10.1038/bjc.1982.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell. 1989;58:573–581. doi: 10.1016/0092-8674(89)90438-8. [DOI] [PubMed] [Google Scholar]
  • 31.Thomassen MJ, Wiedemann HP, Barna BP, Farmer M, Ahmad M. Induction of in vitro tumoricidal activity in alveolar macrophages and monocytes from patients with lung cancer. Cancer Res. 1988;48:3949–3953. [PubMed] [Google Scholar]
  • 32.Vink A, Coulie PG, Warnier G, Renauld JC, Stevens M, Donkers P, Van Snick J. Mouse plasmacytoma growth in vivo: enhancement by interleukin-6 and inhibition by antibodies directed against interleukin-6 or its receptor. J Exp Med. 1990;172:997–1000. doi: 10.1084/jem.172.3.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL-6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol. 1990;20:2439–2443. doi: 10.1002/eji.1830201112. [DOI] [PubMed] [Google Scholar]
  • 34.Walther Z, May LT, Sehgal PB. Transcriptional regulation of the interferon-β2/B cell differentiation factor BSF-2/hepatocyte-stimulating factor gene in human fibroblasts by other cytokines. J Immunol. 1988;140:974–977. [PubMed] [Google Scholar]
  • 35.Weissler JC, Lipscomb MF, Lern VM, Toews GB. Tumor killing by human alveolar macrophages and blod monocytes: Decreased cytotoxicity of human alveolar macrophages. Am Rev Respir Dis. 1986;134:532–537. doi: 10.1164/arrd.1986.134.3.532. [DOI] [PubMed] [Google Scholar]
  • 36.Zhang Y, Lin JX, Vilcek J. Synthesis of interleukin-6 (interferon β2/B cell stimulatory factor 2) in human fibroblast is triggered by an increase in intracellular cyclic AMP. J Biol Chem. 1988;263:6177–6182. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES